Sign In
Buy KMDA
$7.14
+0.0400 (+0.563%)
At Close: Jul 31, 2026
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
07:00am, Wednesday, 11'th Aug 2021
REHOVOT, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
04:48pm, Wednesday, 04'th Aug 2021
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
07:00am, Wednesday, 02'nd Jun 2021
FORT LEE, N.J. and REHOVOT, Israel, June 2, 2021 /PRNewswire/ -- Kedrion Biopharma and Kamada Ltd.
Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call Transcript
12:41pm, Wednesday, 12'th May 2021
Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call Transcript
Kamada (KMDA) Q1 Earnings Top Estimates
11:16am, Wednesday, 12'th May 2021
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
07:00am, Wednesday, 12'th May 2021
REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Ma
Kamada's Earnings Outlook
10:18am, Tuesday, 11'th May 2021
On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
5 Health Care Stocks Trading with Low Price-Earnings Ratios
11:37am, Wednesday, 21'st Apr 2021
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, othe
Checking Back In On Kamada
10:48am, Thursday, 01'st Apr 2021
It has been several years since we last did an in-depth piece on Israeli-based biotech concern Kamada. Early Wednesday, the company disclosed trial results on a candidate being evaluated as a potentia
Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial
07:40am, Wednesday, 31'st Mar 2021
Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the in
REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, singl
Kamada to Present at the Jefferies Global Plasma Summit
07:00am, Tuesday, 09'th Mar 2021
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will pre
Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company
Kamada Files Annual Report for the Year Ended December 31, 2020
07:00am, Wednesday, 24'th Feb 2021
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for t
Kamada's (KMDA) CEO Amir London on Q4 2020 Results - Earnings Call Transcript
10:36pm, Wednesday, 10'th Feb 2021
Kamada's (KMDA) CEO Amir London on Q4 2020 Results - Earnings Call Transcript
